WASHINGTON – Former President Donald Trump is expected to address pharmaceutical drug pricing during a live declaration scheduled for today, October 10, 2025. The move comes as healthcare costs remain a meaningful concern for American voters and follows years of debate over government intervention in the pharmaceutical market.
The announcement is anticipated to detail Trump’s proposals for lowering prescription drug costs, a pledge he frequently made during his initial presidential campaign and throughout his time in office. While specific details remain scarce, the issue has re-emerged as a key political battleground, with both Democrats and Republicans seeking to demonstrate their commitment to affordability. The Biden administration has already taken steps to negotiate lower drug prices through the Inflation Reduction Act, a policy Trump has previously criticized.
According to sources familiar with the planning, the former president’s remarks will likely focus on leveraging government purchasing power and promoting competition within the pharmaceutical industry.However, details regarding the feasibility and potential impact of these proposals are currently unkown. A statement released by a White House spokesperson indicated that any plan “not consistent with the President’s priorities” would face opposition.
Trump’s previous efforts to address drug pricing included proposals to allow the importation of cheaper drugs from Canada and to tie medicare drug prices to international rates. These initiatives faced significant hurdles and ultimately did not achieve widespread implementation.Today’s announcement will be closely watched by industry stakeholders, policymakers, and consumers alike, as it could signal a potential shift in the debate over drug pricing and healthcare policy.
